Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma
Top Cited Papers
Open Access
- 21 January 2016
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 114 (3), 256-261
- https://doi.org/10.1038/bjc.2015.467
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Prognostic score for patients with advanced melanoma treated with ipilimumabEuropean Journal of Cancer, 2015
- Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survivalAnnals of Oncology, 2013
- Improved Survival with MEK Inhibition in BRAF-Mutated MelanomaThe New England Journal of Medicine, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationThe New England Journal of Medicine, 2011
- Final Version of 2009 AJCC Melanoma Staging and ClassificationJournal of Clinical Oncology, 2009
- LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951)European Journal of Cancer, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.2000
- Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic MelanomaJournal of Clinical Oncology, 1999
- Prognostic factors for survival of patients treated systemically for disseminated melanoma.Journal of Clinical Oncology, 1998